Rimantadine

CHEMBL959 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
179.3 g/mol
LogP
2.6
Phase
4

Rimantadine is an adamantane antiviral agent structurally related to amantadine that inhibits the M2 ion channel of influenza A virus, blocking the hydrogen ion influx required for viral uncoating and preventing release of viral RNA into the host cell cytoplasm. It is used for prophylaxis and treatment of influenza A infections, though widespread resistance among circulating influenza A strains has significantly limited its clinical utility.

Peso Molecular

179,3000 g/mol

LogP

2,60

TPSA

26,00 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(N)C12CC3CC(CC(C3)C1)C2

InChI

InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3

Molecular Formula

C12H21N

HBD / HBA

1 / 1

Ligações Rotacionáveis

1

Átomos Pesados

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Rimantadine is an adamantane antiviral agent structurally related to amantadine that inhibits the M2 ion channel of influenza A virus, blocking the hydrogen ion influx required for viral uncoating and preventing release of viral RNA into the host cell cytoplasm. It is used for prophylaxis and treatment of influenza A infections, though widespread resistance among circulating influenza A strains has significantly limited its clinical utility.

Yes, Rimantadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL959. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5071. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.